Human iPS cell-derived cardiomyocytes offer a promising platform for early cardiac safety screening in drug discovery, though challenges in cell maturity and variability remain.
Answers are grounded in this paper and cite their sources.
iPS-cardiomyocyte safety assays advance preclinical screening; leaves open standardized cardiac toxicity evaluation until variability and maturation are resolved.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kanda et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: